A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM

Clinical trial NCT05761301 · TERMINATED

Trial details

NCT number: NCT05761301
Sponsor: Alnylam Pharmaceuticals
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Type 2 Diabetes Mellitus (T2DM)

Start date: 2023-03-10
Primary completion: 2025-04-03
Enrollment: 49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.